The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

Sales of Eli Lilly’s (NYSE:LLY) Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the country following its commercial ...

The weather is still holding up. Thank God for that. Very pleased to kick off our morning session this morning with Eli Lilly. We have Lucas Montarce, CFO; and Mike Czapar, Senior Vice President ...

Shares in Eli Lilly rose sharply in pre-market trading today after the company reported the first phase 3 results for orforglipron, a GLP-1 agonist that it hopes will offer an oral alternative to ...